吸入性β2激动剂与竞技运动员的表现
Inhaled beta2 agonists and performance in competitive athletes.
作者信息
Kindermann W, Meyer T
机构信息
Institute of Sports and Preventive Medicine, Faculty of Clinical Medicine, University of Saarland, Saarbrücken, Germany.
出版信息
Br J Sports Med. 2006 Jul;40 Suppl 1(Suppl 1):i43-7. doi: 10.1136/bjsm.2006.027748.
OBJECTIVES
To provide an overview of the current literature on the use of inhaled beta2 agonists in non-asthmatic competitive athletes, and to assess the performance enhancing effect of inhaled beta2 agonists.
METHODS
Review of the literature.
RESULTS
Twenty randomised, placebo controlled studies (19 double blind, one single blind) were located. Only three studies reported a performance enhancing effect of inhaled beta2 agonists. However, methodological shortcomings were most likely responsible for these findings (for example, non-elite athletes, inconsistent results in different tests, subgroups with above-average responsiveness).
CONCLUSIONS
This review reveals that there is no ergogenic potential of inhaled beta2 agonists in non-asthmatic athletes. In view of the epidemiology of asthma in athletes and the considerable workload involved in provision of therapeutic use exemptions the inclusion of inhaled beta2 agonists on the list of prohibited substances should be reconsidered.
目的
综述目前关于非哮喘竞争性运动员使用吸入型β2激动剂的文献，并评估吸入型β2激动剂的增强运动表现作用。
方法
文献综述。
结果
找到20项随机、安慰剂对照研究（19项双盲，1项单盲）。仅有3项研究报告了吸入型β2激动剂的增强运动表现作用。然而，这些结果很可能是由方法学缺陷导致的（例如，非精英运动员、不同测试结果不一致、反应性高于平均水平的亚组）。
结论
本综述表明，吸入型β2激动剂对非哮喘运动员没有提高运动能力的作用。鉴于运动员哮喘的流行病学情况以及提供治疗用药豁免所涉及的大量工作，应重新考虑将吸入型β2激动剂列入禁用物质清单。
Zotero 插件